IMS and Virtify Partner to Deliver Enterprise Content Compliance Solutions to the European Marketplace


Company News Release

Virtify, Inc. and IMS Health (NYSE: RX) have partnered to jointly deliver Enterprise Content Compliance (ECC) solutions to the European marketplace.

The partnership will combine Virtify’s Virtx ECC Software Suite with comprehensive IMS services to help client companies manage regulated content and compliance issues throughout the product continuum. Virtify’s integrated software suite is an XML-based platform for structured content management, global labeling, submissions, and clinical trial disclosure that enables life sciences customers to reduce costs, mitigate risk and accelerate time to peak sales. Together, IMS and Virtify are uniquely qualified to service the needs of life sciences companies, through a combination of industry expertise, solutions, and comprehensive services. With over 50 years of dedicated life sciences experience, the partnership offers:

• Integrated business process consulting, technology, and services delivery
• Scalable structured content management
• Compliant labeling, submissions, and clinical trial disclosure solutions
• 3,000 customers worldwide
• Global presence

According to industry analyst firm IDC, the cost of bringing a new drug to market ranges from $800 million to $1.2 billion with close to a quarter of these costs coming from the content requirements associated with working in a regulatory compliant environment. The Virtx ECC Software Suite is engineered to meet these specific needs in the highly regulated pharmaceutical, biotechnology, medical device, animal health and food sciences industries.

The integrated Virtx Software Suite provides a secure, collaborative online environment for managing and reusing regulated content. It enables customers to manage the processes of submissions, document creation and review, global labeling, clinical trial disclosure and other regulatory management activities from a single platform.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.